See the blog article for more information. These designations apply to recent vintages (the date of certification, if known, is specified in the estate description). The "Growing/vinification type" designation covers certified wines produced by biodynamic or organic methods, sustainably produced wines, and "environmentally friendly" wines that are not officially certified. As well as rum, the group also owns a large number of other spirits brands. This led to the family’‘s exile, although, as they were already established outside of Cuba, in Porto Rico and Mexico, they were able to continue their business, with it later going on to become one of the most popular rum brands in the world. Following the Cuban Revolution and with Fidel Castro now in power, Bacardí’‘s property in Cuba was confiscated by the new regime as, although supporters of the revolution, they opposed the regime’‘s policies. In the 1930s, Bacardí built a new distillery in Porto Rico, in the United States. Prohibition was to Bacardí’‘s benefit, as boatloads of American tourists came to quench their thirst in Cuba, and the company began developing abroad under the impetus of Emilio’‘s step-brother Enrique Schueg. He was eventually named Mayor of Santiago de Cuba in 1899. Business prospered, despite the exile of Facundo’‘s son, Emilio Bacardí, who fought against Spain in the Cuban War of Independence in the late 19th century. The distillery’‘s famous symbol was chosen by Doña Amalia Bacardí, who had found a colony of fruit bats living in the distillery, traditionally considered a symbol of good luck and family unity.
The distillery Bacardiīacardi was founded on 4 February 1862 with the purchase of a distillery in Santiago de Cuba by Don Facundi Bacardi Masso, a wine merchant originally from Sitges in Spain who had emigrated to Cuba in the early 19th century.
The Bacardi Facundo series, composed of Bacardi Eximo, Exquisito and Paraiso, pays tribute to the house’s founder, Don Facundo Bacardi Masso. Facundo Exquisito X23 La Maxima Calidad Cuvée presentationīacardi Facundo Exquisito is a blend of rums aged for between 7 and 23 years, finished in a sherry cask for one month. In September this year, AngioDynamics agreed to acquire a medical diagnostic and device firm, RadiaDyne, which is involved in the designing and development of patient dose monitoring technology to enhance cancer treatment outcomes.Bacardi Of. The laser technology can also be used for the treatment of a variety of PAD lesion types both above and below-the-knee.Įximo Medical CEO Yoel Zabar said: “We believe that AngioDynamics’ existing resources and commercial acumen will enable a large number of patients to benefit from Eximo’s laser technology, and we look forward to extending its utility into other indications within vascular and elsewhere. The technology holds the capacity to minimise the risk of perforation through tissue selectivity, as well as the risk of embolisation to the patient through the availability of aspiration.Įximo’s technology can also be used for the treatment of in-stent restenosis (ISR), a gradual re-narrowing of the artery after a blockage has been previously treated with a stent. The Eximo technology is said to compliment AngioDynamics’ thrombus management and venous insufficiency technologies.ĪngioDynamics president and CEO Jim Clemmer said: “The acquisition of Eximo brings a remarkable, foundational technology to our portfolio that will change the way caregivers deliver treatment to patients with PAD.Įximo’s laser technology, which is differentiated from other major medical devices, is claimed to be the only system that can deliver short, high-powered pulsed-laser energy in 355nm wavelength without disturbing the integrity of its fibre optic cables during atherectomy procedures. Eximo Medical provides 355nm wavelength laser-technology platform
The acquisition will allow AngioDynamics to expand its vascular interventions and therapies (VIT) product portfolio with the addition of Eximo’s advanced laser technology, which secured 510(k) from the US Food and Drug Administration (FDA) to treat peripheral artery disease (PAD). The deal also includes $20m of contingent consideration based on the achievement of certain technical and revenue milestones. The deal expands AngioDynamics’ existing vascular interventions and therapies (VIT) product portfolio by adding Eximo’s laser technologyĪngioDynamics has acquired commercial-stage medical device company Eximo MedicalĪngioDynamics has acquired Israel-based early commercial-stage medical device company Eximo Medical for $46m up-front consideration.
0 kommentar(er)
